CERO Therapeutics gets Nasdaq Panel extension to April 22, 2025 for listing compliance

CERO THERAPEUTICS HOLDINGS, INC.

Nasdaq Panel grants extension to regain compliance with $50M MVLS, $15M MVPHS, and $1.00 bid price requirements.
Company completed 100:1 reverse stock split on Jan 8, 2025; stock closed above $1.00 since then.
Must apply to transfer to Nasdaq Capital Market by Jan 22, 2025 and meet $2.5M stockholders' equity.
Equity raised from committed facility and warrant exercises since Sep 30, 2024; additional capital raising planned.
Company cannot assure success in raising capital or meeting equity requirement by extension date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.